STERIS plc reported fiscal 2027 first quarter revenue of $1.5 billion, a 7% increase from the prior year period, with constant currency organic growth of 6%. Diluted EPS rose to $2.04, while adjusted diluted EPS reached $2.59. The company announced a restructuring plan to consolidate formulated chemistries manufacturing and distribution into a new Center of Excellence in North Carolina, involving closures in St. Louis, Missouri, and Plymouth, Minnesota. STERIS expects pre-tax restructuring charges between $55 million and $70 million, including $40 million to $50 million in cash expenditures, with completion targeted for fiscal 2030. The firm reiterated its full-year revenue growth guidance of 7-8% and adjusted EPS range of $11.10 to $11.30, while raising capital expenditure expectations to approximately $450 million from $375 million due to the new facility investment. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention.